Treatment with RvE1 was previously demonstrated to reduce the expression of NF-kB and COX-2 Our findings suggest that RvE1 treatment may reduce AgNP-induced inflammation in healthy and MetS models via regulation of COX-2 production of proinflammatory mediators. The gene discussed is PTGS2; the disease is metabolic syndrome.